Clorox Short Interest Jumps 30% in a Month Before Thursday's Print

CLX arrives at its October 30 earnings release carrying short interest that has climbed sharply over the past month, even as the stock itself has held up better than that positioning might suggest.

Short sellers have added aggressively over the past four weeks. Short interest now stands at roughly 10.2% of the free float, up 31% over the past month to around 12.4 million shares. The build is concentrated in October: from early-October levels near 9.4 million shares, positions jumped by nearly 3 million shares in the space of two weeks, with the move largely complete by October 9. That is a material and fast accumulation for a large-cap consumer staples name. Days to cover, at 4.1, confirm the position is real size relative to normal trading volume.

The borrow market tells a different story from that aggressive short build. Availability is generous, with roughly 349% of short interest still available to lend, well above the 52-week tightest reading of 185%. Borrowing costs have barely budged, sitting at 0.53%, down slightly over the past week. New shorts have had no difficulty entering positions, and there is no squeeze pressure visible in the lending data. The options market adds a modest note of caution: the put/call ratio has ticked up to 0.94, about 1.1 standard deviations above its 20-day average of 0.88, and has held near that level for much of the past two weeks. Defensive positioning has increased, but the z-score is well short of the extremes the name has seen over the past year, when the PCR reached as high as 1.18.

Analyst opinion has moved firmly against the stock in the run-up. Every major change in the past three weeks has been a target-price cut: JP Morgan lowered its target to $83 on October 19 while maintaining Underweight, Morgan Stanley cut to $87 on October 15, and Citigroup trimmed to $90 on October 14. Barclays, at $80, is now the most bearish on price among the recent movers. The consensus mean sits at $96.35, above the current price of $86.76, but that figure is being dragged down fast. No firm upgraded or initiated with a positive rating. The EPS momentum scores confirm the direction of travel: near-term estimate revision is in the bottom 20% of the market, and the stock ranks in the bottom 12% on short score. The forward earnings yield is one genuine positive, ranking in the 73rd percentile, and the dividend score is high at 88, making CLX relevant to income-oriented holders even as growth-focused investors have been cutting exposure.

The last quarterly print, in August, produced a sharp one-day gain of nearly 10% and a five-day move of almost 13%. That reaction set a high bar. The shares have since given back much of that ground, trading at $86.76 and up only 1.4% over the past week, roughly in line with the median for closest peers including CHD and KMB. The October earnings report will test whether the operating improvement that drove the August beat was durable enough to justify a stock that, despite a 31% short interest build in a month, still trades at a PE of 14.3 and a price-to-book ratio that looks elevated relative to the household products sector.